Factor XIII Deficiency Treatment Market

Factor XIII Deficiency Treatment Market Outlook (2024 to 2034)

The Global Factor XIII Deficiency Treatment Market will be valued at US$ 210.3 million in 2023 and has been forecasted to expand at a noteworthy CAGR of 5.8% to end up at US$ 400.7 Million by 2034.

The patients suffering from factor XIII deficiency can form blood clots but these clots can be easily dissolvable, unstable and they can break easily which may result in uncontrolled bleeding for long period of time. The severity and symptoms of this deficiency varies from person to person which ultimately differs the treatment according to the severity.

In most patients with factor XIII deficiency (80%), bleeding symptoms appear after birth, which includes bleeding from the umbilical stump. Other patients may have only a mild expression of its deficiency which can be observed in the later stages in the life if patient encounters any traumatic injury or surgery.

Factor XIII deficiency is a hereditary disease. With each pregnancy, there is about 25% chance that two carrier parents will transmit both of the mutated genes on to their children. In case the parents are close relatives of each other, the risk is much higher. Thus, in communities where consanguineous marriages are more common, the risk of factor XIII deficiency is higher in the offspring, hence, it is widely seen in such communities.

Factor XIII deficiency treatment involves the usage of factor XIII concentrates. Fresh frozen plasma is one of the most common factors XIII deficiency treatments, especially in regions where the pharmaceutical version of factor XIII concentrates is not available easily. Cryoprecipitate are no longer recommended for factor XIII deficiency treatment because of the risk of infections from viruses and other similar pathogens.

The risk of allergy is also likely with other unknown factors present in the cryoprecipitates. Individuals with factor XIII deficiency are recommended to undergo preventive factor XIII deficiency treatment that includes the use of factor XIII concentrates every 3-4 weeks. The prophylactic factor XIII deficiency treatment is mainly used to prevent bleeding in the brain.

In extremely rare cases, factor XIII deficiency may be caused due to the development of autoantibodies. These autoantibodies are also called inhibitors since they mistakenly attack replacement factor XIII that is used for the factor XIII deficiency treatment. In case the factor XIII deficiency treatment results in the formation of autoantibodies, additional therapy is required along with the factor XIII deficiency treatment. These additional therapies include the usage of immune suppressant drugs.

Report Attributes	Details
Factor XIII Deficiency Treatment Market Size (2023A)	US$ 210.3 Million
Estimated Market Value (2024E)	US$ 228.0 Million
Forecasted Market Value (2034F)	US$ 400.7 Million
Global Market Growth Rate (2024-2034)	5.8% CAGR
North America Market Share (2024)	35.7%
United States Market Growth Rate (2024-2034)	5.9% CAGR
Key Companies Profiled	Grifols; CSL Behring; Octapharma; LFB Group; Novo Nordisk; Other Market Players.

Historic Analysis (2019 to 2023) and Future (2024 to 2034) Pathway Analysis for the Factor XIII Deficiency Treatment Market

The market for factor XIII deficiency treatment grew at a growth rate of 4.9% from 2019 to 2023, and by the end of 2023, it was valued at US$ 210.3 million.

Historical Report Attributes	Details
Market Size (2019A)	US$ 389.8 million
Market Size (2023A)	US$ 210.3 million
Historical CAGR (2019-2023)	7.4%
Forecasted CAGR (2024-2034)	5.8%

• Short Term (2024 to 2028): The continuous innovation in the field of research and development to innovate novel and effective therapies can result in the significant growth of the market in this period. The healthcare investment is rising in the various countries and people are getting more aware with respect to bleeding disorders day by day.
• Long Term (2029 to 2034): From 2029 to 2034, the stabilization of market can takes place as the therapies in the treatment may become widely accepted. The companies will focus on the long term outcomes and personalized treatment. Improved access to treatments in developing regions may result in bolstering the market growth ensuring effective management of bleeding disorders.

On the back of the aforementioned facts, the factor XIII deficiency treatment market is anticipated to grow at a CAGR of 5.8% during the forecast period from 2024-2034.

Market Dynamics

What are the Factors Propelling the Factor XIII Deficiency Treatment Market?

“Increased Awareness and Diagnosis of Rare Bleeding Disorders”

Due to lack of awareness regarding factor XIII deficiency within general public as well as healthcare providers, many individuals remained undiagnosed. The various educational initiatives by patient advocacy groups and healthcare providers has contributed effectively to raise the awareness. These efforts have encouraged factor XIII deficiency as a potential diagnosis for unexplained bleeding symptoms.

The technological advancements in diagnostic solutions including genetic testing and sensitive coagulation assays has also played crucial role in the growth of this market. This has resulted in early and accurate diagnosis of factor XIII deficiency. With the increasing diagnosis rate the demand for effective treatment is also increasing.

Increased awareness and utilization of healthcare has led to the better patient engagement and strict adherence to treatment protocols. With the rise in number of patients diagnosed and treated, there is an increase in the market for factor XIII deficiency therapies, thereby fostering a favorable scenario for the existing and prospective pharmaceutical companies who are primarily engaged in the research and development of treatment options for this rare disorder.

“Advancements in Treatment Options Ensuring Effective Patient Outcome and Improving Quality of Life”

The continuous improvements in treatment techniques is yet another essential factor fueling the rise of the Factor XIII deficiency treatment market. Recently, there has been an increase in the research and development geared towards the treatment options available for patients with Factor XIII deficiency. This was primarily due to the fact that treatment choice was limited if at all in most cases and consisted mainly of transgenic products or fibrinogen concentrates which, while effective, were not always good enough for the different patients.

The response to this need has seen the invention of treatments such as products containing recombinant Factor XIII together with techniques such as gene therapy that can possibly cure the deficiency. These new approaches improve the management of bleeding episodes, and moreover, have determinants of relief that are far beyond what has been imaging treatments.

For example, almost all the recombinant therapies require only a small volume of concentrates to be administered to patients which helps in maintaining consistency and control of the therapy and reduces the chances of management related complications associated with transfusion.

Once more, the further clinical trials and observations consistently prove the new treatments as safe and effective, which boosts the treatment-seeking behavior of patients and the professionals. Therefore, the industry is seeing a rise in the number of products launched. Evolution in treatment options is contributing for the growth of the factor XIII deficiency treatment market.

What are the Challenges Restraining Growth of Factor XIII Deficiency Treatment Market?

“High Treatment Cost and Limited Awareness among Population is affecting the Growth of Market”

There is a significant problem when it comes to the accessibility of available therapies, especially the recombinant Factor XIII products, because of their cost. These treatments can be so expensive that they can cause excessive tension on an individual and their family, especially in countries with little health care, as they have to bear the extremely high costs.

Coverage of insurance concerning rare bleeding disorders is frequently unreliable, which means that most patients incur unnecessary costs, which act as a deterrent to their focused treatment. Therefore, therapy-related costs restrict timely diagnosis and proper management of the disease, which in turn harms the patient and promotes the stunted growth of the market as a whole.

On top of financial constraints, a sad reality is that knowledge and education about factor XIII deficiency is also limited and this hinders market development. Many healthcare providers, especially primary care providers, may lack awareness of this rare disease which causes both underdiagnosis and misdiagnosis.

Some symptoms are either very mild or can be easily confused with other conditions causing a delay in doctors attending to such patients. Even worse is the fact that a significant section of the society has no knowledge on such a problem and so either does not know it exists or the need to see a doctor for it. This is a contributing factor to the low rates of diagnosis seen and how this is impacting on the treatment options that are available.

Factor XIII Deficiency Treatment Market: Regional Outlook

Based on epidemiology, factor XIII deficiency cases are more frequent in regions where consanguineous marriages are more common. Thus, the occurrence of the disorder is most frequent in the Middle East and Africa region. However, a large number of cases go undiagnosed in these regions.

The factor XIII deficiency treatment market has the highest potential in the MEA. Regions such as Canada, Brazil, Mexico, and China are also among the most lucrative regions for the factor XIII deficiency treatment. Europe and Australia have the lowest epidemiology, owing to which the treatment rate for the factor XIII deficiency treatment is low.

Category-wise Insights

Which Treatment Type is expected to Grow Rapidly in the Factor XIII Deficiency Treatment Market?

“Replacement Therapy is expected to Witness a Significant Demand due to its Proven Efficacy”

Demand for replacement therapy is projected to reach at the value of US$ 294.9 Mn in 2034 at a CAGR of 5.9% from 2024 to 2034.

The market for factor XIII deficiency is anticipated to take on a new dimension due to the increase in the use of replacement therapy. As more cases are diagnosed with this condition, it is becoming clear to healthcare professionals that timely treatment of the condition is of utmost importance.

Replacement therapy, especially using recombinant Factor XIII products, solves the problem of deficiencies, thus virtually eliminating the risk of bleeding related complications. The increasing pipeline is broadening the scope of the market.

The new recombinant products are more effective compared to traditional plasma derived products. They also have higher safety profile. Because of these advancements, the risk related to transmission of infectious disease have reduced which ultimately reduces complications associated with transfusions.

The fast-growing number of diagnosed patients coupled with the increased factor XIII deficiency awareness is creating the need for effective replacement options.

Competitive Landscape

Global market for the treatment of factor XIII deficiency features pharmaceutical companies like Grifols, CSL Behring, Octapharma and LFB Group. There are several blood banks that provide fresh frozen plasma. Some of the blood banks that provide fresh frozen plasma for the treatment of factor XIII deficiency, include the global blood fund, world blood bank and other regional blood banks.

Segmentation of Factor XIII Deficiency Treatment Market

• By Treatment Type :

  • Replacement Therapy
  • Fresh Frozen Plasma Treatment
  • Factor XIII Concentrate
  • Supportive Treatment
  • Blood Transfusion
  • Pain Management

• By Patient Type :

  • Congenital Factor XIII Deficiency
  • Acquired Factor XIII Deficiency

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Blood Banks

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa